Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SMMT |
---|---|---|
09:32 ET | 26605 | 19.76 |
09:34 ET | 25348 | 19.7399 |
09:36 ET | 28655 | 19.58 |
09:38 ET | 17863 | 19.5756 |
09:39 ET | 57322 | 19.3 |
09:41 ET | 49709 | 19.45 |
09:43 ET | 25657 | 19.355 |
09:45 ET | 23801 | 19.38 |
09:48 ET | 28739 | 19.5301 |
09:50 ET | 23201 | 19.585 |
09:52 ET | 11066 | 19.675 |
09:54 ET | 12913 | 19.71 |
09:56 ET | 14194 | 19.78 |
09:57 ET | 13890 | 19.795 |
09:59 ET | 25149 | 19.965 |
10:01 ET | 15791 | 19.885 |
10:03 ET | 31938 | 20.03 |
10:06 ET | 36959 | 20.32 |
10:08 ET | 39717 | 20 |
10:10 ET | 14149 | 19.975 |
10:12 ET | 25126 | 19.99 |
10:14 ET | 21179 | 20.01 |
10:15 ET | 33271 | 19.88 |
10:17 ET | 42184 | 19.76 |
10:19 ET | 13734 | 19.81 |
10:21 ET | 27455 | 19.96 |
10:24 ET | 13507 | 19.875 |
10:26 ET | 19302 | 19.77 |
10:28 ET | 10779 | 19.745 |
10:30 ET | 13482 | 19.89 |
10:32 ET | 13997 | 19.96 |
10:33 ET | 12862 | 19.95 |
10:35 ET | 11620 | 19.92 |
10:37 ET | 13027 | 19.95 |
10:39 ET | 15571 | 19.9699 |
10:42 ET | 17714 | 20 |
10:44 ET | 11909 | 19.96 |
10:46 ET | 13081 | 19.92 |
10:48 ET | 11288 | 19.99 |
10:50 ET | 22666 | 20.2288 |
10:51 ET | 14590 | 20.22 |
10:53 ET | 13316 | 19.96 |
10:55 ET | 32643 | 19.89 |
10:57 ET | 20450 | 19.95 |
11:00 ET | 17471 | 19.885 |
11:02 ET | 10606 | 19.905 |
11:04 ET | 16237 | 19.87 |
11:06 ET | 16175 | 19.93 |
11:08 ET | 25176 | 19.87 |
11:09 ET | 27105 | 19.79 |
11:11 ET | 17216 | 19.6559 |
11:13 ET | 24440 | 19.625 |
11:15 ET | 20252 | 19.66 |
11:18 ET | 13301 | 19.72 |
11:20 ET | 15853 | 19.695 |
11:22 ET | 19099 | 19.7683 |
11:24 ET | 17708 | 19.7 |
11:26 ET | 14060 | 19.67 |
11:27 ET | 23241 | 19.61 |
11:29 ET | 27080 | 19.63 |
11:31 ET | 41465 | 19.67 |
11:33 ET | 22492 | 19.67 |
11:36 ET | 11215 | 19.595 |
11:38 ET | 15541 | 19.66 |
11:40 ET | 12509 | 19.66 |
11:42 ET | 12479 | 19.64 |
11:44 ET | 63000 | 19.56 |
11:45 ET | 100858 | 19.61 |
11:47 ET | 15589 | 19.545 |
11:49 ET | 16087 | 19.6 |
11:51 ET | 23208 | 19.72 |
11:54 ET | 11502 | 19.58 |
11:56 ET | 15805 | 19.54 |
11:58 ET | 16926 | 19.5 |
12:00 ET | 22882 | 19.59 |
12:02 ET | 10981 | 19.6199 |
12:03 ET | 10165 | 19.647 |
12:05 ET | 12144 | 19.645 |
12:07 ET | 15093 | 19.705 |
12:09 ET | 7194 | 19.69 |
12:12 ET | 20363 | 19.7 |
12:14 ET | 10159 | 19.71 |
12:16 ET | 12008 | 19.735 |
12:18 ET | 8270 | 19.69 |
12:20 ET | 9834 | 19.65 |
12:21 ET | 6977 | 19.57 |
12:23 ET | 9035 | 19.675 |
12:25 ET | 8033 | 19.695 |
12:27 ET | 6479 | 19.68 |
12:30 ET | 13744 | 19.64 |
12:32 ET | 8395 | 19.58 |
12:34 ET | 9319 | 19.61 |
12:36 ET | 5024 | 19.61 |
12:38 ET | 10611 | 19.59 |
12:39 ET | 9262 | 19.66 |
12:41 ET | 7223 | 19.595 |
12:43 ET | 8378 | 19.535 |
12:45 ET | 21450 | 19.5667 |
12:48 ET | 5925 | 19.61 |
12:50 ET | 13767 | 19.59 |
12:52 ET | 9285 | 19.56 |
12:54 ET | 6965 | 19.56 |
12:56 ET | 6278 | 19.5 |
12:57 ET | 9815 | 19.495 |
12:59 ET | 47172 | 19.41 |
01:01 ET | 23256 | 19.41 |
01:03 ET | 12182 | 19.41 |
01:06 ET | 24979 | 19.36 |
01:08 ET | 5653 | 19.38 |
01:10 ET | 24215 | 19.28 |
01:12 ET | 24000 | 19.26 |
01:14 ET | 12228 | 19.2604 |
01:15 ET | 6167 | 19.26 |
01:17 ET | 8054 | 19.26 |
01:19 ET | 16825 | 19.25 |
01:21 ET | 10151 | 19.32 |
01:24 ET | 15213 | 19.336 |
01:26 ET | 16514 | 19.37 |
01:28 ET | 15767 | 19.37 |
01:30 ET | 15809 | 19.475 |
01:32 ET | 17864 | 19.405 |
01:33 ET | 6815 | 19.475 |
01:35 ET | 6855 | 19.4199 |
01:37 ET | 8532 | 19.4 |
01:39 ET | 12034 | 19.47 |
01:42 ET | 2776 | 19.55 |
01:44 ET | 8780 | 19.515 |
01:46 ET | 13131 | 19.565 |
01:48 ET | 6234 | 19.58 |
01:50 ET | 12728 | 19.63 |
01:51 ET | 3656 | 19.6 |
01:53 ET | 10915 | 19.61 |
01:55 ET | 4785 | 19.61 |
01:57 ET | 4932 | 19.56 |
02:00 ET | 4054 | 19.5791 |
02:02 ET | 6384 | 19.57 |
02:04 ET | 2900 | 19.54 |
02:06 ET | 10051 | 19.59 |
02:08 ET | 8062 | 19.59 |
02:09 ET | 5944 | 19.6 |
02:11 ET | 4194 | 19.625 |
02:13 ET | 13440 | 19.65 |
02:15 ET | 6142 | 19.675 |
02:18 ET | 13459 | 19.62 |
02:20 ET | 4585 | 19.625 |
02:22 ET | 5456 | 19.675 |
02:24 ET | 5062 | 19.665 |
02:26 ET | 4143 | 19.64 |
02:27 ET | 8652 | 19.63 |
02:29 ET | 8701 | 19.57 |
02:31 ET | 6976 | 19.58 |
02:33 ET | 5766 | 19.61 |
02:36 ET | 7666 | 19.64 |
02:38 ET | 4931 | 19.67 |
02:40 ET | 9361 | 19.6046 |
02:42 ET | 4096 | 19.655 |
02:44 ET | 5161 | 19.62 |
02:45 ET | 5699 | 19.63 |
02:47 ET | 4511 | 19.63 |
02:49 ET | 5898 | 19.63 |
02:51 ET | 4983 | 19.62 |
02:54 ET | 4716 | 19.58 |
02:56 ET | 8977 | 19.62 |
02:58 ET | 7153 | 19.59 |
03:00 ET | 3322 | 19.6 |
03:02 ET | 8450 | 19.6 |
03:03 ET | 7027 | 19.6 |
03:05 ET | 10537 | 19.63 |
03:07 ET | 3928 | 19.61 |
03:09 ET | 6723 | 19.63 |
03:12 ET | 10524 | 19.55 |
03:14 ET | 21494 | 19.505 |
03:16 ET | 8849 | 19.57 |
03:18 ET | 10304 | 19.57 |
03:20 ET | 7942 | 19.59 |
03:21 ET | 8842 | 19.6 |
03:23 ET | 9677 | 19.56 |
03:25 ET | 28550 | 19.52 |
03:27 ET | 11469 | 19.53 |
03:30 ET | 10449 | 19.56 |
03:32 ET | 10797 | 19.52 |
03:34 ET | 10062 | 19.489 |
03:36 ET | 9041 | 19.5314 |
03:38 ET | 13328 | 19.53 |
03:39 ET | 10788 | 19.48 |
03:41 ET | 7085 | 19.545 |
03:43 ET | 16032 | 19.53 |
03:45 ET | 14542 | 19.55 |
03:48 ET | 11579 | 19.57 |
03:50 ET | 14219 | 19.58 |
03:52 ET | 21115 | 19.61 |
03:54 ET | 25797 | 19.72 |
03:56 ET | 39778 | 19.78 |
03:57 ET | 41967 | 19.65 |
03:59 ET | 428117 | 19.54 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Summit Therapeutics Inc | 14.4B | -85.0x | --- |
Vaxcyte Inc | 15.2B | -24.7x | --- |
Insmed Inc | 12.5B | -13.5x | --- |
Ascendis Pharma A/S | 8.9B | -15.3x | --- |
Revolution Medicines Inc | 7.7B | -12.6x | --- |
Viking Therapeutics Inc | 7.2B | -69.0x | --- |
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $14.4B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 735.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.93 |
EPS | $-0.23 |
Book Value | $0.11 |
P/E Ratio | -85.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.